연구동향 분석
박사

림프절 전이가 있는 미만성 위암의 전체 엑솜 염기서열분석을 통한 유전체 분석

이다근 2015년

논문상세정보
인용/피인용
' 림프절 전이가 있는 미만성 위암의 전체 엑솜 염기서열분석을 통한 유전체 분석' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • diffuse-type
  • gastric cancer
  • metastasis
  • whole exome sequencing
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
459 0

0.0%

' 림프절 전이가 있는 미만성 위암의 전체 엑솜 염기서열분석을 통한 유전체 분석' 의 참고문헌

  • Zhang, X., et al., Characterizing the expression of the human olfactoryreceptor gene family using a novel DNA microarray. Genome Biol, 2007.8(5): p. R86.
  • Zang, Z.J., et al., Exome sequencing of gastric adenocarcinoma identifiesrecurrent somatic mutations in cell adhesion and chromatin remodelinggenes. Nat Genet, 2012. 44(5): p. 570-4.
  • Yoo, H.Y., et al., A recurrent inactivating mutation in RHOA GTPase inangioimmunoblastic T cell lymphoma. Nat Genet, 2014. 46(4): p. 371-5.
  • Wong, S.S., et al., Genomic landscape and genetic heterogeneity ingastric adenocarcinoma revealed by whole-genome sequencing. NatCommun, 2014. 5: p. 5477.
  • Warde-Farley, D., et al., The GeneMANIA prediction server: biologicalnetwork integration for gene prioritization and predicting gene function.Nucleic Acids Res, 2010. 38(Web Server issue): p. W214-20.
  • Wang, K., et al., Whole-genome sequencing and comprehensive molecularprofiling identify new driver mutations in gastric cancer. Nat Genet, 2014.46(6): p. 573-82.
  • Wang, K., et al., Exome sequencing identifies frequent mutation ofARID1A in molecular subtypes of gastric cancer. Nat Genet, 2011.43(12): p. 1219-23.
  • Wang, K., M. Li, and H. Hakonarson, ANNOVAR: functional annotationof genetic variants from high-throughput sequencing data. Nucleic AcidsRes, 2010. 38(16): p. e164.
  • Vogelstein, B., et al., Cancer genome landscapes. Science, 2013.339(6127): p. 1546-58.
  • Sargent, D.J., et al., Defective mismatch repair as a predictive markerfor lack of efficacy of fluorouracil-based adjuvant therapy in coloncancer. J Clin Oncol, 2010. 28(20): p. 3219-26.
  • Sanz, G., et al., Promotion of cancer cell invasiveness and metastasisemergence caused by olfactory receptor stimulation. PLoS One, 2014.9(1): p. e85110.
  • Sanui, T., et al., DOCK2 regulates Rac activation and cytoskeletalreorganization through interaction with ELMO1. Blood, 2003. 102(8): p.2948-50.
  • Sander, E.E., et al., Matrix-dependent Tiam1/Rac signaling in epithelialcells promotes either cell-cell adhesion or cell migration and is regulatedby phosphatidylinositol 3-kinase. J Cell Biol, 1998. 143(5): p. 1385-98.
  • Ray, A., M. Alalem, and B.K. Ray, Insulin signaling network in cancer.Indian J Biochem Biophys, 2014. 51(6): p. 493-8.
  • Prickett, T.D., et al., Analysis of the tyrosine kinome in melanomareveals recurrent mutations in ERBB4. Nat Genet, 2009. 41(10): p.1127-32.
  • Peleteiro, B., et al., Model-based patterns in stomach cancer mortalityworldwide. Eur J Cancer Prev, 2014. 23(6): p. 524-31.
  • Pecina-Slaus, N., Tumor suppressor gene E-cadherin and its role innormal and malignant cells. Cancer Cell Int, 2003. 3(1): p. 17.
  • Pan, Y., et al., Expression of seven main Rho family members in gastriccarcinoma. Biochem Biophys Res Commun, 2004. 315(3): p. 686-91.
  • Novotny, A.R., et al., Predicting individual survival after gastric cancerresection: validation of a U.S.-derived nomogram at a single high-volumecenter in Europe. Ann Surg, 2006. 243(1): p. 74-81.
  • Nishihara, H., et al., Non-adherent cell-specific expression of DOCK2, amember of the human CDM-family proteins. Biochim Biophys Acta, 1999.1452(2): p. 179-87.
  • Nishihara, H., et al., DOCK2 associates with CrkL and regulates Rac1 inhuman leukemia cell lines. Blood, 2002. 100(12): p. 3968-74.
  • Neuhaus, E.M., et al., Activation of an olfactory receptor inhibitsproliferation of prostate cancer cells. J Biol Chem, 2009. 284(24): p.16218-25.
  • Muranen, T.A., et al., Breast tumors from CHEK2 1100delC-mutationcarriers: genomic landscape and clinical implications. Breast Cancer Res,2011. 13(5): p. R90.
  • Li, H. and R. Durbin, Fast and accurate short read alignment withBurrows-Wheeler transform. Bioinformatics, 2009. 25(14): p. 1754-60.
  • Lee, Y.S., et al., Genomic profile analysis of diffuse-type gastric cancers.Genome Biol, 2014. 15(4): p. R55.
  • Lee, J., et al., Phase III trial comparing capecitabine plus cisplatinversus capecitabine plus cisplatin with concurrent capecitabineradiotherapy in completely resected gastric cancer with D2 lymph nodedissection: the ARTIST trial. J Clin Oncol, 2012. 30(3): p. 268-73.
  • Lawrence, M.S., et al., Mutational heterogeneity in cancer and the searchfor new cancer-associated genes. Nature, 2013. 499(7457): p. 214-8.
  • Kissil, J.L., et al., Requirement for Rac1 in a K-ras induced lung cancerin the mouse. Cancer Res, 2007. 67(17): p. 8089-94.
  • Keller, A., et al., Genetic variation in a human odorant receptor altersodour perception. Nature, 2007. 449(7161): p. 468-72.
  • Kakiuchi, M., et al., Recurrent gain-of-function mutations of RHOA indiffuse-type gastric carcinoma. Nat Genet, 2014. 46(6): p. 583-7.
  • Huang da, W., B.T. Sherman, and R.A. Lempicki, Systematic andintegrative analysis of large gene lists using DAVID bioinformaticsresources. Nat Protoc, 2009. 4(1): p. 44-57.
  • Hodis, E., et al., A landscape of driver mutations in melanoma. Cell,2012. 150(2): p. 251-63.
  • Henson, D.E., et al., Differential trends in the intestinal and diffuse typesof gastric carcinoma in the United States, 1973-2000: increase in thesignet ring cell type. Arch Pathol Lab Med, 2004. 128(7): p. 765-70.
  • Harris, R.S., Cancer mutation signatures, DNA damage mechanisms, andpotential clinical implications. Genome Med, 2013. 5(9): p. 87.
  • Hammer, J.A., 3rd and X.S. Wu, Rabs grab motors: defining theconnections between Rab GTPases and motor proteins. Curr Opin CellBiol, 2002. 14(1): p. 69-75.
  • Hall, A. and G. Lalli, Rho and Ras GTPases in axon growth, guidance,and branching. Cold Spring Harb Perspect Biol, 2010. 2(2): p. a001818.
  • Gomez del Pulgar, T., et al., Rho GTPase expression in tumourigenesis:evidence for a significant link. Bioessays, 2005. 27(6): p. 602-13.
  • Fukui, Y., et al., Haematopoietic cell-specific CDM family proteinDOCK2 is essential for lymphocyte migration. Nature, 2001. 412(6849): p.826-31.
  • Flegel, C., et al., Expression profile of ectopic olfactory receptorsdetermined by deep sequencing. PLoS One, 2013. 8(2): p. e55368.
  • Ferlay, J., et al., Cancer incidence and mortality worldwide: sources,methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015.136(5): p. E359-86.
  • Esaki, Y., R. Hirayama, and K. Hirokawa, A comparison of patterns ofmetastasis in gastric cancer by histologic type and age. Cancer, 1990.65(9): p. 2086-90.
  • Dulak, A.M., et al., Exome and whole-genome sequencing of esophagealadenocarcinoma identifies recurrent driver events and mutationalcomplexity. Nat Genet, 2013. 45(5): p. 478-86.
  • DePristo, M.A., et al., A framework for variation discovery andgenotyping using next-generation DNA sequencing data. Nat Genet, 2011.43(5): p. 491-498.
  • Cunningham, S.C., et al., Survival after gastric adenocarcinoma resection:eighteen-year experience at a single institution. J Gastrointest Surg, 2005.9(5): p. 718-25.
  • Corso, G., et al., Somatic mutations and deletions of the E-cadherin genepredict poor survival of patients with gastric cancer. J Clin Oncol, 2013.31(7): p. 868-75.
  • Comprehensive molecular characterization of gastric adenocarcinoma.Nature, 2014. 513(7517): p. 202-9.
  • Cibulskis, K., et al., Sensitive detection of somatic point mutations inimpure and heterogeneous cancer samples. Nat Biotechnol, 2013. 31(3): p.213-9.
  • Chiaravalli, A.M., et al., The role of histological investigation inprognostic evaluation of advanced gastric cancer. Analysis of histologicalstructure and molecular changes compared with invasive pattern andstage. Virchows Arch, 2001. 439(2): p. 158-69.
  • Chen, K., et al., Mutational landscape of gastric adenocarcinoma inChinese: Implications for prognosis and therapy. Proc Natl Acad Sci U SA, 2015. 112(4): p. 1107-12.
  • Chedotal, A., G. Kerjan, and C. Moreau-Fauvarque, The brain within thetumor: new roles for axon guidance molecules in cancers. Cell DeathDiffer, 2005. 12(8): p. 1044-56.
  • Cancer Genome Atlas Research, N., Comprehensive molecularcharacterization of gastric adenocarcinoma. Nature, 2014. 513(7517): p.202-9.
  • Becker, K.F., et al., E-cadherin gene mutations provide clues to diffusetype gastric carcinomas. Cancer Res, 1994. 54(14): p. 3845-52.
  • Bang, Y.J., et al., Trastuzumab in combination with chemotherapy versuschemotherapy alone for treatment of HER2-positive advanced gastric orgastro-oesophageal junction cancer (ToGA): a phase 3, open-label,randomised controlled trial. Lancet, 2010. 376(9742): p. 687-97.
  • Alexandrov, L.B., et al., Signatures of mutational processes in humancancer. Nature, 2013. 500(7463): p. 415-21.
  • Agrawal, N., et al., Comparative genomic analysis of esophagealadenocarcinoma and squamous cell carcinoma. Cancer Discov, 2012.2(10): p. 899-905.